文献速递神经核医学

痴呆综合征中的淀粉样蛋白PET:一项中国多中心研究

Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study.
PubMed 文献 · J Nucl Med · 2020-05-08

该多中心研究纳入1193例认知障碍患者,评估多种痴呆综合征及轻度认知障碍(MCI)中β-淀粉样蛋白沉积的患病率。结果显示AD患者淀粉样蛋白阳性率为86.8%,MCI为9.7%,额颞叶痴呆为5.6%,血管性痴呆为20.7%。淀粉样蛋白PET可能有助于痴呆鉴别诊断,尤其区分AD与额颞叶痴呆,并可结合ApoEε4等位基因检测。

要点

  • AD患者淀粉样蛋白阳性率为86.8%(833/960),MCI患者为9.7%(14/144)。
  • 额颞叶痴呆患者β-淀粉样蛋白沉积患病率为5.6%(2/36)。
  • 淀粉样蛋白阳性认知障碍患者ApoEε4等位基因频率为30.5%,显著高于淀粉样蛋白阴性患者(14%)和对照组(7.3%)。

核心结论

  • 淀粉样蛋白显像可能潜在是痴呆鉴别诊断中最有帮助的参数,尤其有助于区分阿尔茨海默病与额颞叶痴呆。
  • 淀粉样蛋白PET可与ApoEε4等位基因遗传风险检测联合用于淀粉样蛋白沉积的评估。

研究设计与样本

  • 多中心研究,连续纳入1193例接受11C-PIB PET或18F-AV45 PET或两者均接受的认知障碍患者。
  • 基线临床诊断独立确立,未参考PET显像结果。
  • 对认知障碍患者及231例性别和年龄匹配的对照者进行了载脂蛋白E(ApoE)基因型分析。

主要发现

  • 1193例认知障碍患者中,860例(72.1%)为淀粉样蛋白阳性。
  • AD和MCI患者的淀粉样蛋白阳性率分别为86.8%(833/960)和9.7%(14/144)。
  • 额颞叶痴呆患者中β-淀粉样蛋白沉积患病率为5.6%(2/36)。
  • 4例皮质基底综合征患者中2例淀粉样蛋白阳性;5例路易体痴呆患者中3例淀粉样蛋白阳性;29例血管性痴呆患者中6例(20.7%)淀粉样蛋白阳性。
  • 淀粉样蛋白阳性认知障碍患者ApoEε4等位基因频率为30.5%,显著高于其他淀粉样蛋白阴性认知障碍患者(14%)或对照组(7.3%)。

关键数值与推荐

  • AD患者淀粉样蛋白阳性率86.8%(833/960)。
  • MCI患者淀粉样蛋白阳性率9.7%(14/144)。
  • 额颞叶痴呆患者β-淀粉样蛋白沉积患病率5.6%(2/36)。
  • 血管性痴呆患者淀粉样蛋白阳性率20.7%(6/29)。
  • 淀粉样蛋白阳性认知障碍患者ApoEε4等位基因频率30.5%,淀粉样蛋白阴性认知障碍患者14%,对照组7.3%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cerebral β-amyloid deposits and regional glucose metabolism assessed by PET are used to distinguish between Alzheimer disease (AD) and other dementia syndromes. In the present multicenter study, we estimated the prevalence of β-amyloid deposits on PET imaging in a wide variety of dementia syndromes and mild cognitive impairment (MCI) within a memory clinic population. Methods: Of the 1,193 consecutive patients with cognitive impairment (CI) who received 1 11C-PIB PET or 18F-AV45 PET or both 11C-PIB PET and 18F-AV45 PET, 960 were diagnosed with AD, 36 with frontotemporal dementia (FTD), 5 with dementia with Lewy bodies, 144 with MCI, 29 with vascular dementia, 4 with corticobasal syndrome, and 15 with unclassifiable dementia. Baseline clinical diagnoses were independently established without access to PET imaging results. Apolipoprotein E (ApoE) genotype analysis was performed on CI patients and 231 sex- and age-matched controls. Results: Of the 1,193 CI patients, 860 (72.1%) were amyloid-positive. The prevalence of amyloid positivity in AD and MCI patients was 86.8% (833/960) and 9.7% (14/144), respectively. In FTD patients, the prevalence of β-amyloid deposits was 5.6% (2/36). In the 4 corticobasal syndrome patients, 2 were amyloid-positive. Three of the 5 patients with dementia with Lewy bodies showed amyloid positivity, as did 6 of the 29 vascular dementia (20.7%) patients. The ApoEε4 allele frequency was significantly increased in amyloid-positive CI patients (30.5%) as compared with other amyloid-negative CI patients (14%) or controls (7.3%). Conclusion: Amyloid imaging may potentially be the most helpful parameter for differential diagnosis in dementia, particularly to distinguish between AD and FTD. Amyloid PET can be used in conjunction with the ApoEε4 allele genetic risk test for amyloid deposits.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Shi Z, Fu LP, Zhang N, et al. Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study. J Nucl Med. 2020. PMID: 32385166. doi:10.2967/jnumed.119.240325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。